TY - JOUR
T1 - The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
AU - Johnson, Kai C.C.
AU - Ni, Ai
AU - Quiroga, Dionisia
AU - Pariser, Ashley C.
AU - Sudheendra, Preeti K.
AU - Williams, Nicole O.
AU - Sardesai, Sagar D.
AU - Cherian, Mathew
AU - Stover, Daniel G.
AU - Gatti-Mays, Margaret
AU - Ramaswamy, Bhuvaneswari
AU - Lustberg, Maryam
AU - Jhawar, Sachin
AU - Skoracki, Roman
AU - Wesolowski, Robert
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between 2010 to 2021 who received locoregional therapy alone or in combination with adjuvant trastuzumab (+/− chemotherapy). Primary outcomes were invasive disease-free survival (iDFS) and overall survival (OS). Of the 1,184 patients, 436 received locoregional therapy alone. We found a statistically significant improvement in iDFS (HR 0.73, P = 0.003) and OS (HR 0.63, P = 0.023) on univariate analysis with adjuvant trastuzumab with or without chemotherapy which remained statistically significant on multivariate analysis. Three-arm univariate analysis found that iDFS was significantly improved with trastuzumab monotherapy (P = 0.003) and combination therapy (P = 0.027) compared to observation. Subgroup data suggests that T1b/c tumors derive the greatest benefit.
AB - There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between 2010 to 2021 who received locoregional therapy alone or in combination with adjuvant trastuzumab (+/− chemotherapy). Primary outcomes were invasive disease-free survival (iDFS) and overall survival (OS). Of the 1,184 patients, 436 received locoregional therapy alone. We found a statistically significant improvement in iDFS (HR 0.73, P = 0.003) and OS (HR 0.63, P = 0.023) on univariate analysis with adjuvant trastuzumab with or without chemotherapy which remained statistically significant on multivariate analysis. Three-arm univariate analysis found that iDFS was significantly improved with trastuzumab monotherapy (P = 0.003) and combination therapy (P = 0.027) compared to observation. Subgroup data suggests that T1b/c tumors derive the greatest benefit.
UR - http://www.scopus.com/inward/record.url?scp=85196285198&partnerID=8YFLogxK
U2 - 10.1038/s41523-024-00652-4
DO - 10.1038/s41523-024-00652-4
M3 - Article
AN - SCOPUS:85196285198
SN - 2374-4677
VL - 10
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 49
ER -